Immunophenoscore (IPS) is of significant value in predicting response to anti-CTLA-4 and anti-PD-1 regimens, by quantifying the determinants of tumor immunogenicity and depicting the intratumoral immune landscapes and cancer antigenomes. Here, CTLA4 is linked to neoplasm.